Advertisement
Advertisement
IMVT
Immunovant, Inc. Common Stock
24.73
USDSponsored
+0.89
+3.75%
Mar 25, 16:00 UTC -4
Closed
After-Market
24.88
+0.14
+0.58%
IMVT Earnings Reports
Positive Surprise Ratio
IMVT beat 11 of 24 last estimates.
46%
Next Report
Date of Next Report
May 27, 2026
Estimate for Q4 26 (Revenue/ EPS)
--
/-$0.61
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-4.69%
Immunovant, Inc. Common Stock earnings per share and revenue
On Feb 06, 2026, IMVT reported earnings of -0.61 USD per share (EPS) for Q3 26, beating the estimate of -0.72 USD, resulting in a 16.27% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +12.43% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 17 analysts forecast an EPS of -0.61 USD, with revenue projected to reach -- USD, implying an increase of 0.00% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.52
Actual
-$3.24
Surprise
-112.47%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Sutro Biopharma, Inc.
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$4.43
Actual
-$5.29
Surprise
-19.39%
Aardvark Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.84
Actual
-$0.81
Surprise
+4.64%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
MAIA Biotechnology, Inc.
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.09
Surprise
+32.13%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Immunovant, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Immunovant, Inc. Common Stock reported EPS of -$0.61, beating estimates by 16.27%, and revenue of $0.00, 0% as expectations.
How did the market react to Immunovant, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 12.43%, changed from $24.06 before the earnings release to $27.05 the day after.
When is Immunovant, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 27, 2026.
What are the forecasts for Immunovant, Inc. Common Stock's next earnings report?
Based on 17
analysts, Immunovant, Inc. Common Stock is expected to report EPS of -$0.61 and revenue of -- for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement